Squarepoint’s Verrica Pharmaceuticals VRCA Stock Holding History

Squarepoint’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$398K	Buy	75,208 +41,938	+126%	+$269K	﹤0.01%	3494
2025 Q4	$276K	Buy	+33,270	New	+$184K	﹤0.01%	3664
2025 Q2	–	Sell	-1,129	Closed	-$4.99K	–	5112
2025 Q1	$4.99K	Buy	+1,129	New	+$7.3K	﹤0.01%	4470
2024 Q4	–	Sell	-8,604	Closed	-$125K	–	5545
2024 Q3	$125K	Buy	+8,604	New	+$388K	﹤0.01%	3825
2023 Q4	–	Sell	-1,687	Closed	-$65.6K	–	4551
2023 Q3	$65.6K	Buy	+1,687	New	+$85.7K	﹤0.01%	3610
2023 Q2	–	Sell	-2,340	Closed	-$152K	–	4057
2023 Q1	$152K	Buy	+2,340	New	+$142K	﹤0.01%	2889
2022 Q3	–	Sell	-1,881	Closed	-$36K	–	3483
2022 Q2	$36K	Buy	+1,881	New	+$94.5K	﹤0.01%	2737
2020 Q2	–	Sell	-4,197	Closed	-$459K	–	2534
2020 Q1	$459K	Sell	4,197 -1,012	-19%	-$133K	0.01%	1091
2019 Q4	$828K	Buy	+5,209	New	+$769K	﹤0.01%	1455

Other funds holding VRCA

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's VRCA Position: Q1 2026 in Review

Squarepoint increased its Verrica Pharmaceuticals (VRCA) stake by 126% in Q1 2026, buying an estimated $269K and bringing the position to 75,208 shares worth $398K. The position accounts for ﹤0.01% of the portfolio, ranked #3494.

Squarepoint first reported a position in VRCA in Q4 2019 and has held it in 9 quarters since. The position peaked at $828K in Q4 2019. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

Squarepoint held 75,208 shares of Verrica Pharmaceuticals worth $398K as of Q1 2026.
Squarepoint bought 41,938 Verrica Pharmaceuticals shares in Q1 2026, an estimated $269K.
Verrica Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3494 holding.
Squarepoint first reported a position in Verrica Pharmaceuticals in Q4 2019 and has held it in 9 quarters since.
Squarepoint's Verrica Pharmaceuticals position peaked at $828K in Q4 2019.
39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.